News
Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn
Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Patients
Deep Dive: Patients & Partnerships 2024
IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Market Access
Looking to history to prepare for America’s uncertain future
In this podcast episode, Jesse Mendelsohn and Nicole Raleigh discuss what the future might hold for pharma under a second Trump Administration
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
Oncology
Partner Content
9th Liquid Biopsy for Precision Oncology Summit
9th Liquid Biopsy for Precision Oncology Summit | February 18-20, 2025 | San Diego, CA | FREE* to Attend for Biopharma
R&D
Partner Content
9th Commercialising Continuous Processing Summit 2025
The pivotal shift in biopharma priorities is steering towards enhancing sustainability measures for drug development.
Category :
Views & Analysis
/
